All News

At EAU 2026, Adam B. Weiner, MD, spoke with Nikita Bhatt, MD, about the growing interest in prehabilitation to optimize patients ahead of cystectomy.

Enolen implants demonstrated minimal systemic drug exposure and early signals of tumor volume reduction in localized prostate cancer.

The NCCN has recognized NAI plus BCG as an option for BCG-unresponsive papillary NMIBC as FDA review continues.

The OPTIMUM randomized trial demonstrated that microultrasonography-guided biopsy is noninferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer, with a streamlined in-office workflow, a manageable learning curve, and substantially lower cost that may help address diagnostic access gaps worldwide.

64Cu-SAR-bisPSMA demonstrated higher lesion detection rates, improved diagnostic accuracy, and a substantial impact on clinical management.

Adam B. Weiner, MD, sits down with Giancarlo Marra, MD, at EAU 2026 to discuss transperineal vs transrectal biopsy for prostate cancer diagnosis.

A subgroup analysis of the POTOMAC trial showed that durvalumab plus BCG I+M had consistent safety and efficacy in older patients with BCG-naïve high-risk NMIBC.

Clearance of the non-permanent implant technology is backed by safety and efficacy results from the pivotal Expander-2 trial.

Data showed that the addition of PSMA-PET/CT reduced the need for prostate biopsy by nearly half without compromising the detection of clinically significant prostate cancer.

Katy Beckermann, MD, PhD, discusses how emerging data from the LITESPARK trials—particularly LITESPARK-011 and LITESPARK-022—may expand the role of belzutifan-based combinations across renal cell carcinoma treatment, while emphasizing the clinical significance of durable responses, careful toxicity management, and the need for longer-term survival data to guide practice.

"Emerging evidence indicates that molecular imaging may enable more accurate detection of primary RCC, improve surveillance for recurrence, and enhance identification of metastatic lesions compared with conventional imaging," write the authors.

Lutetium-177 rosopatamab tetraxetan demonstrated an acceptable safety and tolerability profile with no new safety signals in patients with PSMA-positive mCRPC.

Neal D. Shore, MD, FACS, shares key findings from a post hoc analysis of the EMBARK trial showing that sustained PSA responses are possible following only 9 months of treatment with enzalutamide plus leuprolide.

Robert J. Motzer, MD, discusses the scientific rationale for the LITESPARK-011 study, its design and key findings, and how this combination could potentially influence treatment strategies in renal cell carcinoma.

Results from the AMPLIFY trial are intended to support an FDA submission seeking approval of 64Cu-SAR-bisPSMA as a diagnostic imaging agent for BCR of prostate cancer.

ImmunityBio has resubmitted an sBLA for the combination following an FDA request for updated efficacy data.

“Once we actually get a J code for a medication, it really solidifies the amount of reimbursement that's going to occur,” says Jonathan Rubenstein, MD.

NDV-01, a sustained-release intravesical combo, delivered durable 12‑month complete responses in high-risk NMIBC, particularly among patients with BCG-unresponsive disease.

According to Lantheus, Pylarify TruVu is formulated to improve product stability at higher radioactive concentrations, facilitating more efficient manufacturing and distribution.

Sadashiv Bhole, MBBS, MS (Surgery), MCh (Urology), DNB (Genito-Urinary Surgery), FMASI, offers an in-depth perspective on how robotic platforms are being adopted across India.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, speaks with Christian D. Fankhauser, MD, MPH, about the evolving role of biomarkers in testicular cancer.

A central theme is the widening gap between clinical work and health care policy.

FX-909, a first-in-class PPARγ inverse agonist, demonstrated manageable toxicity and preliminary antitumor activity in patients with advanced urothelial carcinoma.

At SUFU 2026, 24-month data from the TITAN 2 trial showed that the Altaviva ITNM system provided sustained reductions in urgency urinary incontinence episodes, durable quality-of-life improvements, and a favorable safety profile through 24 months.

ImmunityBio plans to submit a biologics license application to the FDA by Q4 of 2026.